| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
| (43) |
Date of publication of application: |
|
17.09.2014 Bulletin 2014/38 |
| (73) |
Proprietors: |
|
- CymaBay Therapeutics, Inc.
Newark, CA 94560 (US)
- DiaTex, Inc.
San Antonio, TX 78248 (US)
|
|
| (72) |
Inventors: |
|
- LAVAN, Brian Edward
NEWARK
CA 94560 (US)
- SAHA, Gopal Chandra
NEWARK
CA 94560 (US)
- ROBERTS, Brian K.
NEWARK
CA 94560 (US)
- MCWHERTER, Charles A.
NEWARK
CA 94560 (US)
|
| (74) |
Representative: Wills, Andrew Jonathan et al |
|
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE
London EC2V 5DE (GB) |
| (56) |
References cited: :
US-A1- 2011 268 801
|
US-B1- 6 613 802
|
|
| |
|
|
- BLUHM G B ET AL: "A double blind study comparing halofenate with probenecid in gout",
ARTHRITIS & RHEUMATISM, WILEY, US, vol. 18, no. 4, 1 January 1975 (1975-01-01), pages
388-389, XP009183634, ISSN: 0004-3591
- ANONYMOUS: "METABOLEX INITIATES PHASE 2 TRIAL OF ARHALOFENATE Potential Best-in-Class
Uricosuric Agent for the Treatment of Gout", INTERNET CITATION, 19 May 2011 (2011-05-19),
pages 1-2, XP002682224, Retrieved from the Internet: URL:http://www.metabolex.com/news/may19201
1.html [retrieved on 2012-02-11]
- Schlesinger N: "Management of acute and chronic gouty arthritis: present state-of-the-art.
- PubMed - NCBI", , 1 January 2004 (2004-01-01), XP055181670, Retrieved from the Internet:
URL:http://www.ncbi.nlm.nih.gov/pubmed/154 81999 [retrieved on 2015-04-08]
|
|
